1
|
Feneyrolles C, Guiet L, Singer M, Van Hijfte N, Daydé-Cazals B, Fauvel B, Chevé G, Yasri A. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors. Bioorg Med Chem Lett 2017; 27:862-866. [PMID: 28094183 DOI: 10.1016/j.bmcl.2017.01.015] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 12/14/2016] [Accepted: 01/06/2017] [Indexed: 12/27/2022]
Abstract
AXL is a receptor tyrosine kinase that plays a key role in tumor growth and proliferation. The scientific community has validated AXL as therapeutic target in the treatment of cancers for several years now, and several AXL inhibitors have been developed but none of them are approved. In this context, we started to design new kinase inhibitors targeting AXL from the 7-azaindole scaffold well known to interact with the ATP binding site of the kinase. Focused screening and chemical diversification around 7-azaindole scaffold were developed, based on modeling studies and medicinal chemistry rational, leading to the discovery of a new family of hits with potent inhibitory activity against AXL.
Collapse
Affiliation(s)
- Clémence Feneyrolles
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Léa Guiet
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Mathilde Singer
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Nathalie Van Hijfte
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Bénédicte Daydé-Cazals
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Bénédicte Fauvel
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Gwénaël Chevé
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France
| | - Abdelaziz Yasri
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, 34189 Montpellier Cedex 4, France.
| |
Collapse
|
2
|
Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A. Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors. J Med Chem 2016; 59:3886-905. [DOI: 10.1021/acs.jmedchem.6b00087] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Bénédicte Daydé-Cazals
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Bénédicte Fauvel
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Mathilde Singer
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Clémence Feneyrolles
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Benoit Bestgen
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Fanny Gassiot
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Aurélia Spenlinhauer
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Pierre Warnault
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Nathalie Van Hijfte
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Nozha Borjini
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Gwénaël Chevé
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| | - Abdelaziz Yasri
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 1682 rue de la Valsière, CS 17383, Montpellier 34189 CEDEX 4, France
| |
Collapse
|
3
|
Messoussi A, Feneyrolles C, Bros A, Deroide A, Daydé-Cazals B, Chevé G, Van Hijfte N, Fauvel B, Bougrin K, Yasri A. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. ACTA ACUST UNITED AC 2014; 21:1433-43. [PMID: 25442375 DOI: 10.1016/j.chembiol.2014.09.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 08/19/2014] [Accepted: 09/05/2014] [Indexed: 12/11/2022]
Abstract
The c-Jun N-terminal kinase (JNK) family, with its three members JNK1, JNK2, and JNK3, is a subfamily of mitogen-activated protein kinases. Involved in many aspects of cellular processes, JNK has been also associated with pathological states such as neurodegenerative diseases, inflammation, and cancers. In oncology, each isoform plays a distinct role depending on the context of the targeted tissue/organ, the tumor stage, and, most likely, the signaling pathway activated upstream. Consequently, the current challenge in finding new successful anti-JNK therapies is to design isoform-selective inhibitors of the JNKs. In this review, a particular focus is given to the JNK inhibitors that have been developed thus far when examining 3D structures of various JNK-inhibitor complexes. Using current data regarding structure-activity relationships and medicinal chemistry approaches, our objective is to provide a better understanding of the design and development of selective JNK inhibitors in the present and future.
Collapse
Affiliation(s)
- Abdellah Messoussi
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France; Laboratoire de Chimie des Plantes et de Synthèse Organique et Bioorganique, URAC23, Université Mohammed V-Agdal, Faculté des Sciences, B.P. 1014 Rabat, Morocco
| | | | - Aurélie Bros
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France
| | - Arthur Deroide
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France
| | | | - Gwénaël Chevé
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France
| | | | - Bénédicte Fauvel
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France
| | - Khalid Bougrin
- Laboratoire de Chimie des Plantes et de Synthèse Organique et Bioorganique, URAC23, Université Mohammed V-Agdal, Faculté des Sciences, B.P. 1014 Rabat, Morocco
| | - Aziz Yasri
- OriBase Pharma, Cap Gamma, Parc Euromédecine, 34090 Montpellier, France.
| |
Collapse
|
4
|
Messoussi A, Peyronnet L, Feneyrolles C, Chevé G, Bougrin K, Yasri A. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors. Molecules 2014; 19:16223-39. [PMID: 25310149 PMCID: PMC6271404 DOI: 10.3390/molecules191016223] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 09/24/2014] [Accepted: 09/26/2014] [Indexed: 01/24/2023] Open
Abstract
Structural elucidation of the active (DFG-Asp in) and inactive (DFG-Asp out) states of the TAM family of receptor tyrosine kinases is required for future development of TAM inhibitors as drugs. Herein we report a computational study on each of the three TAM members Tyro-3, Axl and Mer. DFG-Asp in and DFG-Asp out homology models of each one were built based on the X-ray structure of c-Met kinase, an enzyme with a closely related sequence. Structural validation and in silico screening enabled identification of critical amino acids for ligand binding within the active site of each DFG-Asp in and DFG-Asp out model. The position and nature of amino acids that differ among Tyro-3, Axl and Mer, and the potential role of these residues in the design of selective TAM ligands, are discussed.
Collapse
Affiliation(s)
- Abdellah Messoussi
- OriBase Pharma, Parc Euromedecine, Cap Gamma, 1682, rue de la Valsière, 34189 Montpellier, France.
| | - Lucile Peyronnet
- OriBase Pharma, Parc Euromedecine, Cap Gamma, 1682, rue de la Valsière, 34189 Montpellier, France.
| | - Clémence Feneyrolles
- OriBase Pharma, Parc Euromedecine, Cap Gamma, 1682, rue de la Valsière, 34189 Montpellier, France.
| | - Gwénaël Chevé
- OriBase Pharma, Parc Euromedecine, Cap Gamma, 1682, rue de la Valsière, 34189 Montpellier, France.
| | - Khalid Bougrin
- Laboratoire de Chimie des Plantes et de Synthèse Organique et Bioorganique, URAC23, Université Mohammed V, Faculté des Sciences B.P., 1014 Rabat, Morocco.
| | - Aziz Yasri
- OriBase Pharma, Parc Euromedecine, Cap Gamma, 1682, rue de la Valsière, 34189 Montpellier, France.
| |
Collapse
|
5
|
Feneyrolles C, Spenlinhauer A, Guiet L, Fauvel B, Daydé-Cazals B, Warnault P, Chevé G, Yasri A. Axl kinase as a key target for oncology: focus on small molecule inhibitors. Mol Cancer Ther 2014; 13:2141-8. [PMID: 25139999 DOI: 10.1158/1535-7163.mct-13-1083] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells. As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways. Its overexpression/overactivation has been underlined in several conditions, especially cancers, and in both chemotherapy and targeted therapy sensitivity loss. In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition. We especially focus on small molecule inhibitors, their structure, inhibition profile, and development stages.
Collapse
Affiliation(s)
| | | | - Léa Guiet
- OriBase Pharma, Cap Gamma, Montpellier, France
| | | | | | | | | | - Aziz Yasri
- OriBase Pharma, Cap Gamma, Montpellier, France
| |
Collapse
|